Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

Clin Transl Oncol. 2024 Apr;26(4):1033-1037. doi: 10.1007/s12094-023-03312-4. Epub 2023 Sep 8.

Abstract

Objective: To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).

Methods: The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.

Results: After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93-3.95).

Conclusions: In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.

Keywords: BRCA; Breast cancer; Carcinosarcoma; Endometrial cancer; Endometrioid carcinoma; Hysterectomy; Mutation; Risk-reducing salpingo-oophorectomy; Serous carcinoma; Tamoxifen.

Publication types

  • Multicenter Study

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Cohort Studies
  • Endometrial Neoplasms* / epidemiology
  • Endometrial Neoplasms* / genetics
  • Female
  • Genes, BRCA1
  • Genes, BRCA2
  • Genetic Predisposition to Disease
  • Humans
  • Mutation
  • Ovarian Neoplasms* / pathology
  • Ovariectomy
  • Salpingo-oophorectomy

Substances

  • BRCA1 protein, human
  • BRCA1 Protein
  • BRCA2 protein, human
  • BRCA2 Protein